Cargando…
Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy
BACKGROUND: While the use of antibiotic prophylaxis is clearly advantageous to prevent streptococcal infection, it alters the composition of the gut microbiota in mothers and infants. Enterococcus faecium L3 is one of the best studied probiotic strains and shows strong antagonistic activity against...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521898/ https://www.ncbi.nlm.nih.gov/pubmed/28112691 |
_version_ | 1785110241490239488 |
---|---|
author | Di Pierro, Francesco Parolari, Annamaria Brundu, Benedetta Nigro, Raffaele |
author_facet | Di Pierro, Francesco Parolari, Annamaria Brundu, Benedetta Nigro, Raffaele |
author_sort | Di Pierro, Francesco |
collection | PubMed |
description | BACKGROUND: While the use of antibiotic prophylaxis is clearly advantageous to prevent streptococcal infection, it alters the composition of the gut microbiota in mothers and infants. Enterococcus faecium L3 is one of the best studied probiotic strains and shows strong antagonistic activity against Streptococcus agalactiae due to the production of bacteriocins able to inhibit common gut and vaginal pathogens. METHODS: We tested an L3-based probiotic formula (iNatal®) on 127 pregnant women attending our gynaecological unit in 2015. We compared the study subjects with 279 pregnant women enrolled in the same year and with 892 other pregnant women who attended our gynaecological unit in 2013 and 2014. RESULTS: The findings demonstrate: (a) the safety profile of the product; (b) its ability to reduce gut disorders; (c) a 6% decrease in the incidence of streptococcal colonization; (d) an approximately 30% decline in episodes of premature rupture of membranes; (e) fewer caesarean sections during labour; and (f) a reduction in pathological umbilical cord blood pH. CONCLUSIONS: Our results demonstrate that a probiotic treatment during pregnancy could have unexpected but favourable clinical results. Further randomized, double-blind, placebo controlled studies are now needed to confirm our preliminary findings. (www.actabiomedica.it) |
format | Online Article Text |
id | pubmed-10521898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Mattioli 1885 |
record_format | MEDLINE/PubMed |
spelling | pubmed-105218982023-09-27 Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy Di Pierro, Francesco Parolari, Annamaria Brundu, Benedetta Nigro, Raffaele Acta Biomed Original Article BACKGROUND: While the use of antibiotic prophylaxis is clearly advantageous to prevent streptococcal infection, it alters the composition of the gut microbiota in mothers and infants. Enterococcus faecium L3 is one of the best studied probiotic strains and shows strong antagonistic activity against Streptococcus agalactiae due to the production of bacteriocins able to inhibit common gut and vaginal pathogens. METHODS: We tested an L3-based probiotic formula (iNatal®) on 127 pregnant women attending our gynaecological unit in 2015. We compared the study subjects with 279 pregnant women enrolled in the same year and with 892 other pregnant women who attended our gynaecological unit in 2013 and 2014. RESULTS: The findings demonstrate: (a) the safety profile of the product; (b) its ability to reduce gut disorders; (c) a 6% decrease in the incidence of streptococcal colonization; (d) an approximately 30% decline in episodes of premature rupture of membranes; (e) fewer caesarean sections during labour; and (f) a reduction in pathological umbilical cord blood pH. CONCLUSIONS: Our results demonstrate that a probiotic treatment during pregnancy could have unexpected but favourable clinical results. Further randomized, double-blind, placebo controlled studies are now needed to confirm our preliminary findings. (www.actabiomedica.it) Mattioli 1885 2016 2016-01-16 /pmc/articles/PMC10521898/ /pubmed/28112691 Text en Copyright: © 2016 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Original Article Di Pierro, Francesco Parolari, Annamaria Brundu, Benedetta Nigro, Raffaele Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy |
title | Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy |
title_full | Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy |
title_fullStr | Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy |
title_full_unstemmed | Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy |
title_short | Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy |
title_sort | positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521898/ https://www.ncbi.nlm.nih.gov/pubmed/28112691 |
work_keys_str_mv | AT dipierrofrancesco positiveclinicaloutcomesderivedfromusingaproprietarymixtureofselectedstrainsduringpregnancy AT parolariannamaria positiveclinicaloutcomesderivedfromusingaproprietarymixtureofselectedstrainsduringpregnancy AT brundubenedetta positiveclinicaloutcomesderivedfromusingaproprietarymixtureofselectedstrainsduringpregnancy AT nigroraffaele positiveclinicaloutcomesderivedfromusingaproprietarymixtureofselectedstrainsduringpregnancy |